Regentis Biomaterials
Founded Year
2004Stage
Grant | AliveTotal Raised
$32.5MAbout Regentis Biomaterials
Regentis Biomaterials is focused on developing and commercializing hydrogels for tissue regeneration. The Gelrin hydrogel platform is a matrix of polyethylene glycol diacrylate (PEG-DA) and denatured fibrinogen, combining the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications. The company's flagship product, GelrinC, for the treatment of articular cartilage lesions, is currently in clinical trials.
Missing: Regentis Biomaterials's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Regentis Biomaterials's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Regentis Biomaterials
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Regentis Biomaterials is included in 4 Expert Collections, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Medical Devices
8,605 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Health IT
7,901 items
Regentis Biomaterials Patents
Regentis Biomaterials has filed 17 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/26/2014 | 10/8/2019 | Biomaterials, Polymers, Tissue engineering, Colloidal chemistry, Polymer chemistry | Grant |
Application Date | 6/26/2014 |
|---|---|
Grant Date | 10/8/2019 |
Title | |
Related Topics | Biomaterials, Polymers, Tissue engineering, Colloidal chemistry, Polymer chemistry |
Status | Grant |
Latest Regentis Biomaterials News
Dec 11, 2022
See original article here -> post ismagilov Israeli regenerative medicine company Regentis BioMaterials (RGBM) has filed for a proposed $15M initial public offering. In its filing,… Related
Regentis Biomaterials Frequently Asked Questions (FAQ)
When was Regentis Biomaterials founded?
Regentis Biomaterials was founded in 2004.
Where is Regentis Biomaterials's headquarters?
Regentis Biomaterials's headquarters is located at Northern Industrial Zone, Or Akiva.
What is Regentis Biomaterials's latest funding round?
Regentis Biomaterials's latest funding round is Grant.
How much did Regentis Biomaterials raise?
Regentis Biomaterials raised a total of $32.5M.
Who are the investors of Regentis Biomaterials?
Investors of Regentis Biomaterials include Horizon 2020, SCP Vitalife, Medica Partners, Technion Research & Development Foundation, Generali Investment and 9 more.
Who are Regentis Biomaterials's competitors?
Competitors of Regentis Biomaterials include OcuNexus Therapeutics, Histogenics, FirstString Research, ETEX Holdings, BioMimetic Therapeutics and 11 more.
Compare Regentis Biomaterials to Competitors
Biofisica develops and markets products for soft tissue wound healing and tissue regeneration based on an exclusive and technology that uses electrical stimulation and hydro-gel materials.
Nanotope is a regenerative medicine company that leverages a core set of technologies to address multiple therapeutic markets. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for wound healing and the treatment of peripheral artery disease.n
AugmentRx has developed a tissue bulking agent to treat stress urinary incontinence. The SOLVE injectable product aims to provide a fully viable alternative to slings, surgical procedures and inferior shorter-acting bulking agents. Per AugmentRx, it is bioinert, non-antigenic, non-migratory, permanent, easy-to-inject, and more affordable and aims to provide long-lasting, sustainable tissue volume.
OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.
Juventas Therapeutics, formerly AcelleRx Therapeutics, Juventas Therapeutics is a privately held, clinical stage biotechnology company focused on developing non-viral gene therapies to treat advanced cardiovascular diseases. The Company's lead product candidate, JVS-100, is a non-viral gene therapy undergoing evaluation in clinical studies for the treatment of advanced cardiovascular diseases.
Isolating diverse creatures including species indegenous to rainforests in Malaysia, exploring new compounds which lead development of new medicine conforming to CBD and building a predominant bio-resource collection, NGS will contribute to health and progress of bioindustries in international community.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.